450 Shares in Quest Diagnostics Incorporated $DGX Purchased by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. bought a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 450 shares of the medical research company’s stock, valued at approximately $76,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DGX. Brighton Jones LLC bought a new position in shares of Quest Diagnostics in the fourth quarter valued at approximately $323,000. Benjamin Edwards Inc. boosted its stake in Quest Diagnostics by 7.0% during the 4th quarter. Benjamin Edwards Inc. now owns 4,673 shares of the medical research company’s stock valued at $705,000 after purchasing an additional 304 shares in the last quarter. Cary Street Partners Financial LLC bought a new position in Quest Diagnostics during the 4th quarter valued at $370,000. Captrust Financial Advisors increased its position in shares of Quest Diagnostics by 4.1% during the 4th quarter. Captrust Financial Advisors now owns 14,452 shares of the medical research company’s stock valued at $2,180,000 after purchasing an additional 567 shares during the period. Finally, Centiva Capital LP bought a new stake in shares of Quest Diagnostics in the 4th quarter worth $484,000. 88.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DGX. Truist Financial raised their target price on Quest Diagnostics from $190.00 to $192.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Quest Diagnostics from $160.00 to $178.00 and gave the company a “hold” rating in a research report on Wednesday, July 23rd. Evercore ISI set a $185.00 target price on shares of Quest Diagnostics in a report on Wednesday, July 23rd. Baird R W lowered shares of Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. Finally, Robert W. Baird restated a “neutral” rating and issued a $194.00 price target on shares of Quest Diagnostics in a research report on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $186.00.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, SVP Patrick Plewman sold 1,975 shares of Quest Diagnostics stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $185.00, for a total transaction of $365,375.00. Following the transaction, the senior vice president owned 15,269 shares of the company’s stock, valued at $2,824,765. The trade was a 11.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Karthik Kuppusamy sold 2,210 shares of the stock in a transaction that occurred on Thursday, July 31st. The stock was sold at an average price of $170.00, for a total transaction of $375,700.00. Following the completion of the sale, the senior vice president directly owned 8,450 shares of the company’s stock, valued at $1,436,500. This trade represents a 20.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,496 shares of company stock valued at $4,278,787 over the last 90 days. Corporate insiders own 8.16% of the company’s stock.

Quest Diagnostics Stock Up 1.8%

DGX stock opened at $183.44 on Friday. The company’s 50 day simple moving average is $175.29 and its 200-day simple moving average is $173.41. Quest Diagnostics Incorporated has a 52-week low of $146.17 and a 52-week high of $185.62. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 0.99. The firm has a market capitalization of $20.51 billion, a P/E ratio of 21.97, a P/E/G ratio of 2.43 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.05. The firm had revenue of $2.76 billion for the quarter, compared to analysts’ expectations of $2.73 billion. Quest Diagnostics had a net margin of 9.01% and a return on equity of 15.24%. The company’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.35 EPS. Quest Diagnostics has set its FY 2025 guidance at 9.630-9.830 EPS. As a group, equities research analysts anticipate that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 20th. Shareholders of record on Friday, October 3rd will be given a dividend of $0.80 per share. The ex-dividend date is Friday, October 3rd. This represents a $3.20 dividend on an annualized basis and a yield of 1.7%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 38.32%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.